Northwest Biotherapeutics, Inc.

Equities

NWBO

US66737P6007

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:59:39 2024-06-07 EDT			5-day change	1st Jan Change
0.4638 ^USD	+0.83%		+2.77%	-33.84%

05-10	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	CI

Northwest Biotherapeutics, Inc. Names to Two Russell Indexes

June 16, 2014 at 08:15 am

Northwest Biotherapeutics announced that it has been added to two Russell Indexes: the Russell Global and the Russell 3,000 Indexes. The preliminary announcement was made on Saturday, June 14, 2014, and becomes effective on June 27, 2014. The Russell 3,000 Index covers both the Russell 2,000 Index for small-cap growth stocks and the Russell 1000 Index for larger-cap companies.

The Russell Global Indexes reflect the performance of over 10,000 securities in 47 countries. Selection for inclusion in these indexes is based upon market capitalization and other market factors relating to a company and its stock.

Latest news about Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	03-21	CI
Northwest Biotherapeutics, Inc. Announces Retirement of Jerry Jasinowski from the Board of Directors	03-14	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma	12-21	CI
Northwest Biotherapeutics, Inc. announced that it has received $11.005 million in funding from Streeterville Capital, LLC	11-09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board	23-09-12	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call	22-12-30
Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation	22-12-01	MT
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma	22-11-17	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Northwest Biotherapeutics Files $250 Million Mixed Shelf	22-10-19	MT
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan by MHRA	22-08-23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing At Sawston, Uk Facility	22-07-06	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-02-28	CI
Northwest Biotherapeutics Announces Commencement of Cancer Vaccine Production At Its Sawston, UK Facility	22-02-17	CI
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility	21-12-21	CI

Chart Northwest Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NORTHWEST BIOTHERAPEUTICS, INC.	-33.84%	564M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs